Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Mangia A; Santoro R; Minerva N; Ricci GL; Carretta V; Persico M; Vinelli F; Scotto G; Bacca D; Annese M; Romano M; Zechini F; Sogari F; Spirito F; Andriulli A; The New England Journal Of Medicine, 2005, vol. 352, issue 25, p 2609, ISSN 15334406. ISBN 15334406.
Full Text Resources Located for this Citation